Helicobacter pylori infectious disease
diseaseOn this page
Also known as Helicobacter infectionHelicobacter pylori caused disease or disorderHelicobacter pylori disease or disorderHelicobacter pylori infection, susceptibility toinfection, Helicobacterinfections, Helicobacter
Summary
Helicobacter pylori infectious disease (MONDO:0006781) is a disease with 2 GWAS associations across 11 studies and 47 clinical trials. Top therapeutic interventions include metronidazole, clarithromycin, and rabeprazole. A subtype of gram-negative bacterial infections — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- GWAS associations: 2
- Clinical trials: 47
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | Helicobacter pylori infectious disease |
| Mondo ID | MONDO:0006781 |
| EFO | EFO:1000961 |
| MeSH | D016481 |
| Is cancer (heuristic) | no |
Also known as: Helicobacter infection · Helicobacter pylori caused disease or disorder · Helicobacter pylori disease or disorder · Helicobacter pylori infection, susceptibility to · infection, Helicobacter · infections, Helicobacter
Data availability: 2 GWAS associations (11 studies).
Disease family
This is a subtype of gram-negative bacterial infections. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › bacterial infectious disease › gram-negative bacterial infections › Helicobacter pylori infectious disease
Related subtypes (14): streptobacillus infectious disease, Bacteroidaceae infectious disease, Desulfovibrionaceae infectious disease, Moraxellaceae infectious disease, Anaplasmataceae infectious disease, Bartonellaceae infectious disease, Fusobacteriaceae infectious disease, Rickettsiaceae infectious disease, Treponema infectious disease, chlamydiaceae infections, bordetellosis, bacterial meningitis caused by gram-negative bacteria, pneumonia caused by gram negative bacteria, burkholderia infectious disease
Genetics & variants
GWAS landscape
2 GWAS associations across 11 studies. Top hits map to 1 distinct genes (as reported by GWAS).
Top associations by p-value
| rsID | p-value | Gene | Risk allele | Odds ratio |
|---|---|---|---|---|
| rs564452884 | 5e-12 | LRRC30 - PTPRM | C | 2.2 |
| rs3745769 | 5e-07 | ZNF568 | ? |
Top studies (by case count)
| Study | Lead author | Year | Cases | Controls | Title |
|---|---|---|---|---|---|
| GCST90652154 | Liu TY | 2025 | 3,321 | 213,110 | Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population. |
| GCST90477044 | Verma A | 2024 | 2,565 | 444,731 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90477043 | Verma A | 2024 | 2,525 | 116,347 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90479747 | Verma A | 2024 | 2,525 | 116,347 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90079571 | Backman JD | 2021 | 1,559 | 386,371 | Exome sequencing and analysis of 454,787 UK Biobank participants. |
| GCST90083557 | Backman JD | 2021 | 1,559 | 386,371 | Exome sequencing and analysis of 454,787 UK Biobank participants. |
| GCST90077849 | Backman JD | 2021 | 1,375 | 330,379 | Exome sequencing and analysis of 454,787 UK Biobank participants. |
| GCST90081835 | Backman JD | 2021 | 1,375 | 330,379 | Exome sequencing and analysis of 454,787 UK Biobank participants. |
| GCST90077850 | Backman JD | 2021 | 1,318 | 327,734 | Exome sequencing and analysis of 454,787 UK Biobank participants. |
| GCST90081836 | Backman JD | 2021 | 1,318 | 327,734 | Exome sequencing and analysis of 454,787 UK Biobank participants. |
Variant details and genetic-evidence tiers
Tier distribution (top 50 variants)
| Tier | Variants |
|---|---|
| Tier 1: coding | 0 |
| Tier 2: splice/UTR | 1 |
| Tier 3: regulatory | 0 |
| Tier 4: intronic/intergenic | 1 |
MAF distribution
| Bucket | Variants |
|---|---|
| common (>=0.05) | 0 |
| low_freq (0.01-0.05) | 0 |
| rare (<0.01) | 1 |
| unknown | 1 |
Functional consequences
| Consequence | Count |
|---|---|
| intron_variant | 1 |
| 3_prime_UTR_variant | 1 |
Top variants
| rsID | Chr | Pos | Alleles | MAF | Consequence | Gene | p-value | Tier |
|---|---|---|---|---|---|---|---|---|
| rs564452884 | 18 | 7522242 | C>T | 0 | intron_variant | LRRC30 - PTPRM | 5e-12 | Tier 4: intronic/intergenic |
| rs3745769 | 19 | 36997721 | G>A | 3_prime_UTR_variant | ZNF568 | 5e-07 | Tier 2: splice/UTR |
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
0 approved, 21 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Amoxicillin | Phase 3 (in late-stage trials) |
| Bismuth Subcitrate | Phase 3 (in late-stage trials) |
| Bismuth Subcitrate Potassium | Phase 3 (in late-stage trials) |
| Bismuth Subsalicylate | Phase 3 (in late-stage trials) |
| Cholecalciferol | Phase 3 (in late-stage trials) |
| Clarithromycin | Phase 3 (in late-stage trials) |
| Clavulanic Acid | Phase 3 (in late-stage trials) |
| Esomeprazole | Phase 3 (in late-stage trials) |
| Gemifloxacin | Phase 3 (in late-stage trials) |
| Lansoprazole | Phase 3 (in late-stage trials) |
| Metronidazole | Phase 3 (in late-stage trials) |
| Moxifloxacin | Phase 3 (in late-stage trials) |
| Nitazoxanide | Phase 3 (in late-stage trials) |
| Omeprazole | Phase 3 (in late-stage trials) |
| Rabeprazole | Phase 3 (in late-stage trials) |
| Rifasutenizol | Phase 3 (in late-stage trials) |
| Rifaximin | Phase 3 (in late-stage trials) |
| Tegoprazan | Phase 3 (in late-stage trials) |
| Tetracycline | Phase 3 (in late-stage trials) |
| Tinidazole | Phase 3 (in late-stage trials) |
| Vonoprazan | Phase 3 (in late-stage trials) |
Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Acetazolamide, Pantoprazole, Ranitidine.
Clinical trials & evidence
Clinical trials
Clinical trials: 47.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 24 |
| PHASE4 | 11 |
| PHASE3 | 6 |
| PHASE2 | 3 |
| PHASE2/PHASE3 | 2 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT07115173 | PHASE4 | NOT_YET_RECRUITING | Clinical Trial to Evaluate the Efficacy of Probit-Based Triple Therapy for Helicobacter Pylori Eradication |
| NCT00216450 | PHASE4 | COMPLETED | Study of the Safety and Effectiveness of Rabeprazole in Treatment of Helicobacter Pylori Infection in Adults. |
| NCT00656968 | PHASE4 | COMPLETED | Comparison of Sequential or Concomitant Therapy for Helicobacter Pylori Infection |
| NCT00816140 | PHASE4 | COMPLETED | Levofloxacin Versus Clarithromycin Triple Therapy in First-Line Treatment for Helicobacter Pylori Eradication |
| NCT00841854 | PHASE4 | COMPLETED | Comparison of 7-day and 14-day Bismuth Based Quadruple Therapy for Secondary Helicobacter Pylori Eradication |
| NCT01163435 | PHASE4 | COMPLETED | Efficacy of High Dose Dual Therapy, Sequential Therapy and Triple Therapy in H. Pylori Eradication |
| NCT01219764 | PHASE4 | COMPLETED | A Trial of Standard vs Half Dose Rabeprazole, Clarithromycin, Metronidazole and Amoxicillin in the Treatment of Helicobacter Pylori Infection |
| NCT01792700 | PHASE4 | COMPLETED | Long-term Follow up Helicobacter Pylori Reinfection Rate After Second-Line Treatment: Bismuth-Containing Quadruple Therapy Versus Moxifloxacin-Based Triple Therapy |
| NCT02395458 | PHASE4 | COMPLETED | Efficacy on Helicobacter Pylori Eradication With Two Antibiotic Regimens |
| NCT02401477 | PHASE4 | COMPLETED | Dual Therapy With High Doses of Ilaprazole and Amoxicillin for Helicobacter Pylori Infection |
| NCT02711176 | PHASE4 | COMPLETED | Comparison of Daily Single Dose Triple and Conventional Triple Therapies for Helicobacter Pylori Infection |
| NCT00149084 | PHASE3 | UNKNOWN | Tailored Treatment of H. Pylori Infection Based Polymorphisms of CYP2C19 and 23S rRNA of H. Pylori |
| NCT00197418 | PHASE2/PHASE3 | UNKNOWN | Second Line Therapy for the Cure of Helicobacter Pylori (H. Pylori) Infection |
| NCT00664209 | PHASE3 | TERMINATED | Treating H. Pylori in Parkinson’s Patients With Motor Fluctuations |
| NCT00669955 | PHASE3 | COMPLETED | Efficacy and Safety of Quadruple Therapy in Eradication of H. Pylori: A Comparison to Triple Therapy |
| NCT02051348 | PHASE2/PHASE3 | COMPLETED | Study of Pylopass Versus Placebo in Subjects Who Are Helicobacter Pylori Carriers and With Mild Indigestion |
| NCT03491995 | PHASE3 | UNKNOWN | A Unique Regimen for Treatment of Helicobacter Pylori Infection |
| NCT04652284 | PHASE3 | UNKNOWN | Effectiveness of Rifabutin for Treatment of Helicobacter Pylori |
| NCT05863858 | PHASE3 | COMPLETED | Eradication of H. Pylori Infection With Moxifloxacin |
| NCT07293910 | PHASE2 | RECRUITING | Vonoprazan vs Proton Pump Inhibitor With Vitamin D or Probiotics Based Triple Therapy for Eradication of Helicobacter Pylori Infection |
| NCT00194688 | PHASE2 | COMPLETED | Breath Ammonia Method for H. Pylori Detection: Phase II |
| NCT00723502 | PHASE2 | COMPLETED | Efficacy and Safety Study of Finafloxacin Used in Helicobacter Pylori Infected Patients |
| NCT00483158 | PHASE1 | COMPLETED | First Time in Man Study of Finafloxacin Hydrochloride |
| NCT01133951 | Not specified | ACTIVE_NOT_RECRUITING | Helicobacter Pylori Eradication to Prevent Gastric Cancer |
| NCT02373280 | Not specified | RECRUITING | The Efficacy of the 7 Days Tailored Therapy as the 1st Eradication of H. Pylori Infection |
| NCT03365609 | Not specified | RECRUITING | A Comparison of Four Different Treatment Regimens of Helicobacter Pylori in Chinese Children |
| NCT05247112 | Not specified | RECRUITING | Prevalence and Trends of Antimicrobial Resistance of Helicobacter Pylori in Korea |
| NCT06896370 | Not specified | RECRUITING | An Observational Study for Gastric Cancer in Carriers of High Risk Helicobacter Pylori |
| NCT07293169 | Not specified | NOT_YET_RECRUITING | Helicobacter Pylori Infection Among Women With Recurrent Abortion of Unknown Cause |
| NCT00005496 | Not specified | COMPLETED | Inflammation, Infection, and Future Cardiovascular Risk |
| NCT00005547 | Not specified | COMPLETED | Infection and Cardiovascular Disease |
| NCT00083291 | Not specified | COMPLETED | Helicobacter Pylori and Dry Eye |
| NCT00212225 | Not specified | COMPLETED | Risk Factors for Gastric Disease in Pediatric Helicobacter Pylori (H. Pylori) |
| NCT00490386 | Not specified | COMPLETED | Helicobacter Pylori and Acute Alcohol Induced Pancreatitis |
| NCT01723059 | Not specified | UNKNOWN | Standard Triple Therapy vs Sequential Therapy in Treatment of H Pylori Infection |
| NCT01922505 | Not specified | COMPLETED | Eradication Rates of Helicobacter Pylori and Its Affecting Factors |
| NCT02126722 | Not specified | UNKNOWN | Endofaster Test for Helicobacter Pylori Detection in Patients on Proton Pump Inhibitor Therapy |
| NCT02349685 | Not specified | COMPLETED | The Efficacy of the Tailored Therapy Based on Antimicrobial Susceptibility for 2nd Eradication of H. Pylori |
| NCT02352701 | Not specified | COMPLETED | Efficacy and Safety of Basic Triple Therapy Including Ilaprazole on the First Line Eradication Treatment of H.Pylori |
| NCT02359331 | Not specified | TERMINATED | The Efficacy of the 7 Days Tailored Therapy as 2nd Rescue Therapy for Eradication of H. Pylori Infection |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| METRONIDAZOLE | 4 | 6 |
| CLARITHROMYCIN | 4 | 5 |
| RABEPRAZOLE | 4 | 5 |
| AMOXICILLIN | 4 | 3 |
| OMEPRAZOLE | 4 | 3 |
| TETRACYCLINE | 4 | 3 |
| ESOMEPRAZOLE | 4 | 2 |
| FINAFLOXACIN | 4 | 2 |
| LANSOPRAZOLE | 4 | 1 |
| MOXIFLOXACIN | 4 | 1 |
| PANTOPRAZOLE | 4 | 1 |
| RIFABUTIN | 4 | 1 |
| TINIDAZOLE | 4 | 1 |
| ILAPRAZOLE | 3 | 1 |
| CHEMBL3137673 | 0 | 1 |